Efgartigimod for generalized myasthenia gravis: A multicenter real‐world cohort study in China

Abstract Objective Efgartigimod, a neonatal Fc receptor antagonist, facilitates antibody degradation including pathogenic IgGs. The ADAPT study demonstrated the tolerability and efficacy of efgartigimod in the treatment of generalized myasthenia gravis (gMG). However, very limited evidence is availa...

詳細記述

書誌詳細

主要な著者:	Sushan Luo, Qilong Jiang, Wenshuang Zeng, Qinzhou Wang, Zhangyu Zou, Yanyan Yu, Daojun Hong, Quantao Zeng, Song Tan, Zhouao Zhang, Yong Zhang, Xiuming Guo, Jing Chen, Zhongyan Zhao, Shixiong Huang, Jianquan Shi, Ying Chen, Lei Du, Chong Yan, Jianying Xi, Jie Song, Chongbo Zhao, the Chinese Myasthenia Gravis Collaborating Group (CMGCG)
フォーマット:	Artigo
言語:	Inglês
出版事項:	Wiley 2024-08-01
シリーズ:	Annals of Clinical and Translational Neurology
オンライン･アクセス:	https://doi.org/10.1002/acn3.52142
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!